Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial

Timothy Craig, Markus Magerl, Donald S. Levy, Avner Reshef, William R. Lumry, Inmaculada Martinez-Saguer, Joshua S. Jacobs, William H. Yang, Bruce Ritchie, Emel Aygören-Pürsün, Paul K. Keith, Paula Busse, Henrike Feuersenger, Dipti Pawaskar, Iris Jacobs, Ingo Pragst, Mittie K. Doyle

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Fingerprint

Dive into the research topics of 'Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences